Use of Melphalan Flufenamide Plus Dexamethasone for Multiple Myeloma

Paul Richardson, MD, Dana-Farber Cancer Institute, discusses the background and findings of his study on the use of melphalan flufenamide in combination with dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least 4 lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.

Related Presenters